Nuformix plc (LON:NFX)
London flag London · Delayed Price · Currency is GBP · Price in GBX
0.0844
-0.0006 (-0.71%)
Jul 22, 2025, 12:07 PM BST

Nuformix Company Description

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.

The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology.

It has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

Nuformix plc
Nuformix logo
CountryUnited Kingdom
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees3

Contact Details

Address:
60 Gracechurch Street
London, EC3V 0HR
United Kingdom
Phone44 12 2362 7222
Websitenuformix.com

Stock Details

Ticker SymbolNFX
ExchangeLondon Stock Exchange
Fiscal YearOctober - September
Reporting CurrencyGBP
ISIN NumberGB00BYW79Y38
SIC Code2834

Key Executives

NamePosition
Dr. Daniel John GoodingExecutive Director
Dr. Joanne M. HollandConsultant
Shaun ZulafqarCompany Secretary